Bispecific Antibody Development for Breast Cancer

Introduction of Bispecific Antibody

Bispecific antibodies (BsAb ) are a class of engineered antibodies that combine the specific binding domains of two different mAb's into a single molecule, which allows them to interact with two different targets simultaneously, facilitating a variety of therapeutic strategies. BsAb have emerged as a promising approach for the treatment of Breast Cancer (BC), providing unique functionality for both targeted therapy and immunomodulation. This function targets tumor-associated antigens (TAA) on BC cells while engaging immune effector cells or blocking key signaling pathways. Several preclinical and clinical studies have demonstrated the potential of BsAb in BC therapy. For example, BsAb targeting HER2 has been shown to redirect immune cells to HER2-positive BC cells, resulting in effective tumor cell killing.

Fig. 1. Three types of BsAb. (Lan HR, et al., 2023)

Bispecific Antibody Development Services

Alfa Cytology has extensive expertise and experience in recombinant antibody production, providing fast and efficient bispecific antibody expression services. Utilizing optimized and proven expression platforms, production can begin from antibody sequences and facilitate the expression of multiple bispecific antibody formats.

We provide bispecific antibodies of different structures to meet the different needs of customers:

• CrossMAb

CrossMAb technology reduces light chain mismatches and is often used in combination with other formats such as KiH, DEEK and ART-Ig. This method promotes the correct assembly of bispecific antibody (bsAb) light chains by exchanging heavy and light chain regions on one side.

• BiTE

BiTE is a tandem scFv that contains two scFvs. One scFv binds to CD3 on T cells, and the other binds to tumor cell surface antigens, thereby instructing T cells to eliminate tumor cells.

• DutaMab

DutaMab is designed with a variable region that recognizes two unrelated antigens. This is achieved through two binding sites (paratopes) on the antibody, taking advantage of the diversity of only three complementarity-determining regions per antigen.

• DVD-IgG

DVD-IgG is formed from two parent monoclonal antibodies. Instead of using just one variable domain, two variable domains from one parent antibody are fused to the heavy and light chains of the other parent antibody.

Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world in BC research. We can provide you with BC bispecific antibody development services and help in the development of therapies and diagnostics for BC. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.